Search Results

• • 15 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer--From "MAYBE" to "MUST BE".

  1

  The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer--From "MAYBE" to "MUST BE".

  Author:Takayuki YoshinoFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20211,040 words Article 1820LRemarkable advances in precision oncology over the last 2 decades have highlighted the necessity for genotyping in patients with advanced cancers to ensure appropriate therapy selection. Practice guidelines outlined by...
• Select COMMENTARY By.

  2

  COMMENTARY By.

  Author:Sandra CuellarFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20211,350 words Interview 1150LQ: Can you briefly describe margetuximab's mechanism of action? A: The mechanism of action of margetuximab [Margenza] is exciting; we're now moving into this new era of monoclonal antibody technology. We've been using...
• Select Investigators Look Past Standard Immunotherapy for Additional Lung Cancer Solutions: "That's the beauty of science. Anything can be intellectual.".

  3

  Investigators Look Past Standard Immunotherapy for Additional Lung Cancer Solutions: "That's the beauty of science. Anything can be intellectual.".

  Author:Roman Perez-SolerFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20211,495 words Interview 1150LImmunotherapy has cemented itself as a standard of care across multiple lung cancer indications, but investigators continue to seek solutions that may help broader patient populations in the future. Roman Perez-Soler,...
• Select Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.

  4

  Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.

  Authors:Bethany Smith, Sungjin Kim, Mourad Tighiouart, Edwin Posadas, Leland Chung, Robert Figlin, et al.From:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20213,608 words Article 1820LBACKGROUND: Glutamine uptake has been shown to contribute to local prostate cancer growth and therapeutic resistance. We investigated the biomarker potential of glutamine among known prognostic variables in localized...
• Select Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy.

  5

  Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy.

  Author:Eytan M. SteinFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20212,543 words Article 1880LAlthough the standard treatment for acute myeloid leukemia (AML) involves intensive induction chemotherapy, many diagnosed patients are ineligible because of advanced age and preexisting comorbidities. (1)...
• Select Scientific Progress Involves Research Findings With Missed End Points.

  6

  Scientific Progress Involves Research Findings With Missed End Points.

  Authors:Kristie L. Kahl, Audrey Sternberg, Hayley Virgil, Matthew Fowler, Ariana Pelosci, Jennifer Potash, et al.From:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 2021579 words Article 1810LRegular consumers of scientific journals are often presented with a picture of trials or studies with highly statistically significant data rejecting the null hypothesis and potentially practice-changing implication in...
• Select Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response.

  7

  Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response.

  Authors:George Ansstas and Firas B. BadinFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20211,043 words Clinical report 1450LDespite the broad success of immunotherapy across different solid tumor and hematologic malignancies, reliable biomarkers of response to immune checkpoint blockade have eluded investigators, creating an unmet medical...
• Select Transforming Outcomes in Multiple Myeloma With Antibody-Based Regimens.

  8

  Transforming Outcomes in Multiple Myeloma With Antibody-Based Regimens.

  Author:Graham JacksonFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20213,890 words Article 1450LFACULTY, STAFF, AND PLANNERS' DISCLOSURES In accordance with ACCME Guidelines, PER[R] has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep...
• Select Addressing Stress and Burnout in Hematology/Oncology Physicians.

  9

  Addressing Stress and Burnout in Hematology/Oncology Physicians.

  Author:Julie M. VoseFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 2021487 words Article 1540LEven prior to the COVID-19 pandemic, hematology/oncology physicians who specialize in the care of patients with cancer reported high levels of symptoms consistent with burnout, including frustration (78%), emotional...
• Select Why Hybrid Care Starts With the Patient.

  10

  Why Hybrid Care Starts With the Patient.

  From:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 2021406 words Article 1320LWith the emergence of the COVID-19 virus, health care providers were forced to move many appointments to telehealth in order to connect with patients safely. In a study by McKinsey & Company, providers saw 50 to 175...
• Select EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Margetuximab for HER2-Positive Breast Cancer.

  11

  EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Margetuximab for HER2-Positive Breast Cancer.

  From:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 2021349 words Brief article 1120LProduct Profile Drug name: Margetuximab (Margenza) Date of approval: December 16, 2020 Initial indication: for use in combination with chemotherapy for adult patients with metastatic HER2-positive breast cancer...
• Select Advanced Urothelial Cancer: Updates in Frontline Systemic Therapy.

  12

  Advanced Urothelial Cancer: Updates in Frontline Systemic Therapy.

  Authors:Petros Grivas, Guru P. Sonpavde, Thomas Powles, and Neeraj AgarwalFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20211,987 words Article 1440LThe treatment of urothelial cancer can present challenges given the tendency for patients with early-stage tumors to experience rapid progression to advanced disease following standard management. Additionally, recent...
• Select The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform.

  13

  The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform.

  Authors:Kristen K. Ciombor, Jeremy C. Jones, John Strickler, Tanios S. Bekaii-Saab, and Christina WuFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20213,945 words Article 1800LMetastatic Colorectal Cancer and Treatment Challenges Colorectal cancer (CRC) is estimated to be the third most prevalent cause of cancer death in both men and women in the United States in 2021. (1) While some...
• Select Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.

  14

  Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma.

  Authors:Nora Sobrevilla-Moreno, Daniel Rivera-Sanchez, Dorian Y. Garcia-Ortega, Diego Lopez-Macias, Alexandra Garcilazo-Reyes, Miguel A. Alvarez-Avitia, et al.From:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20212,891 words Article 1780LWhich of the following is true about the treatment of oligoprogressive disease in patients with metastatic melanoma? A. Time from surgery to recurrence does not affect the benefit of a surgical approach. B....
• Select Updates in HER2-Positive Metastatic Breast Cancer.

  15

  Updates in HER2-Positive Metastatic Breast Cancer.

  Authors:V.K. Gadi, Neil Iyengar, Claudine Isaacs, and Virginia KaklamaniFrom:Oncology (Vol. 35, Issue 9) Peer-Reviewed

  Sept. 20212,287 words Article 1470LThe recent approval of novel HER2-targeted therapies has improved options for the treatment of patients with HER2-positive metastatic breast cancer (mBC), particularly those with brain metastases. More data are needed on...